Phase II study of concurrent chemoradiation in combination with erlotinib for locally advanced esophageal carcinoma.

[1]  Y. Lu,et al.  Gefitinib versus platinum contained doublet chemotherapy in chemotherapy-naive patients with stage IIIb or IV non-small cell lung cancer of adenocarcinoma histology: A retrospective case control study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  C. Rudin,et al.  Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  C. Xie,et al.  [Concurrent chemoradiation with paclitaxel and platinum for locally advanced esophageal cancer]. , 2007, Zhonghua zhong liu za zhi [Chinese journal of oncology].

[4]  A. Ardizzoni,et al.  B3-06: Interim safety results from TRUST, a global open-label study of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC) , 2007 .

[5]  C. Ferreira,et al.  Phase II study of erlotinib combined with cisplatin and radiotherapy for locally advanced squamous cell carcinoma of the head and neck (SCCHN) , 2007 .

[6]  Suzanne L Wolden,et al.  Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Christopher U. Jones,et al.  Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. , 2006, The New England journal of medicine.

[8]  M. Dobelbower,et al.  Epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5-fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer: a phase I study , 2006, Anti-Cancer Drugs.

[9]  T. Fujiwara,et al.  ZD1839 (Gefitinib, ‘Iressa’), an epidermal growth factor receptor‐tyrosine kinase inhibitor, enhances the anti‐cancer effects of TRAIL in human esophageal squamous cell carcinoma , 2005, FEBS letters.

[10]  S. Varambally,et al.  Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). , 2005, Cancer research.

[11]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[12]  Masahiro Fukuoka,et al.  Gefitinib — a novel targeted approach to treating cancer , 2004, Nature Reviews Cancer.

[13]  D. Ferry,et al.  Phase II trial of gefitinib (ZD1839) in advanced adenocarcinoma of the oesophagus incorporating biopsy before and after gefitinib , 2004 .

[14]  M. Bains,et al.  Phase I trial of combined-modality therapy for localized esophageal cancer: escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  H. Kuwano,et al.  Genetic Alterations in Esophageal Cancer , 2004, Surgery Today.

[16]  Tsung-Teh Wu,et al.  Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  W. Hohenberger,et al.  Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  J. Ciezki,et al.  Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  H. Friess,et al.  Concomitant Analysis of the Epidermal Growth Factor Receptor Family in Esophageal Cancer: Overexpression of Epidermal Growth Factor Receptor mRNA but Not of c-erbB-2 and c-erbB-3 , 1999, World Journal of Surgery.

[20]  G. Schwartz,et al.  Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  J. Lokich,et al.  Combined paclitaxel, cisplatin, and etoposide for patients with previously untreated esophageal and gastroesophageal carcinomas , 1999, Cancer.

[22]  J. Cooper,et al.  Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. , 1999, JAMA.

[23]  J. Fraumeni,et al.  Changing patterns in the incidence of esophageal and gastric carcinoma in the United States , 1998, Cancer.

[24]  J. Ajani,et al.  Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  J. Bosset,et al.  Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. , 1997, The New England journal of medicine.

[26]  M. Shannon,et al.  The effect of ionizing radiation on signal transduction: antibodies to EGF receptor sensitize A431 cells to radiation. , 1996, Biochimica et biophysica acta.

[27]  T. Walsh,et al.  A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. , 1996, The New England journal of medicine.

[28]  H. Shiozaki.  [Mechanism of the lymph node metastasis in human esophageal cancer (epidermal growth factor causes the dysfunction of cadherin-mediated cell-cell adhesion)]. , 1996, Human cell.

[29]  H. Sasano,et al.  Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification , 1994, Cancer.

[30]  J. Ajani,et al.  Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. , 1994, Journal of the National Cancer Institute.

[31]  F Demard,et al.  Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Y. Doki,et al.  Prognostic significance of transforming growth factor‐α in human esophageal carcinoma implication for the autocrine proliferation , 1993, Cancer.

[33]  J. Wong,et al.  Postoperative radiotherapy for carcinoma of the esophagus: a prospective, randomized controlled study. , 1993, Surgery.

[34]  M. Ueda.  [New prognostic factors in patients with esophageal squamous carcinoma]. , 1992, Gan to kagaku ryoho. Cancer & chemotherapy.

[35]  N. Shimizu,et al.  Prognostic significance of epidermal growth factor receptor in esophageal squamous cell carcinomas , 1989, Cancer.

[36]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .